BioSpace News Archive

Assistance for UnitedHealthcare plan participants whose access to care or prescriptions needs may have been affected

Collegiate, alumnae members unite in Memphis to recognize raising more than $68 million for the hospital

Experienced leader of oncology clinical trial approvals to head BioAtla’s clinical development programs

PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has completed their review of a proposed indication extension of Translarna™ for the treatment of patients with nonsense mutation Duchenne muscular dystrophy who are non-ambulatory.

Growth Achieved in Revenue and Business Diversification Synergies from Each Business Segment, Steady Expansion in New Biomedical Businesses

Lannett Company, Inc. announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg.

Neovasc Inc. announced that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Common Share for every ten pre-Consolidation Common Shares.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent®, recommending to extend its approval in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

Aimmune Therapeutics, Inc. announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17.

Newron Pharmaceutical S.p.A., announces that it has received Tranche 1 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria.